GlassScriptPhysician profile
Harry S Sahi
NPI 1689720021
$1,454.53
in general payments reported to CMS, 2019-2025
25 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $26.32 · 2023: $340 · 2024: $389 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.37 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $450.47 | 2023-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $281.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $133.99 | 2019-2025 | Shingrix, Arexvy |
| Shield Therapeutics INC | $82.68 | 2025 | |
| Sunovion Pharmaceuticals INC. | $79.74 | 2019 | |
| Lilly USA, LLC | $56.47 | 2019-2025 | Mounjaro, Zepbound |
| Biofire Diagnostics, LLC | $48.41 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.99 | 2020-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $25.27 | 2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $24.36 | 2024 | |
| Boston Scientific Corporation | $24.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.04 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.36 | 2025 | Eliquis |
| Phathom Pharmaceuticals, INC. | $19.70 | 2024 | Voquezna |
| Strongbridge US INC. | $19.50 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.72 | 2023 | Myrbetriq |
| Inspire Medical Systems, INC. | $17.38 | 2023 | Inspire |
| Exact Sciences Corporation | $17.18 | 2023 | Cologuard Collection Kit |
| Tactile Systems Technology INC | $16.04 | 2023 | Flexitouch Plus, Entre Plus |
| Alnylam Pharmaceuticals INC. | $14.09 | 2023 | Onpattro |
| Amgen INC. | $13.74 | 2024 | Otezla, Repatha |
| Pfizer INC. | $13.22 | 2024 | |
| Allergan, INC. | $12.95 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.77 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Sahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.